Trial Profile
The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs PEPIDH1M (Primary) ; Diphtheria toxoid; Montanide ISA-51; Temozolomide; Tetanus toxoid
- Indications Glioma; Medulloblastoma
- Focus Adverse reactions
- Acronyms PRiME
- 31 Mar 2023 Planned End Date changed from 1 Dec 2024 to 1 Apr 2025.
- 31 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2023.
- 31 Mar 2023 Status changed from recruiting to active, no longer recruiting.